Transcatheter Mitral-Valve Repair in Patients with Heart Failure
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients with heart failure who have mitral regurgitation due to left ventricular dysfunction, the prognosis is poor. Transcatheter mitral-valve repair may improve their clinical outcomes. METHODS: At 78 sites in the United States and Canada, we enrolled patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite the use of maximal doses of guideline-directed medical therapy. Patients were randomly assigned to transcatheter mitral-valve repair plus medical therapy (device group) or medical therapy alone (control group). The primary effectiveness end point was all hospitalizations for heart failure within 24 months of follow-up. The primary safety end point was freedom from device-related complications at 12 months; the rate for this end point was compared with a prespecified objective performance goal of 88.0%. RESULTS: Of the 614 patients who were enrolled in the trial, 302 were assigned to the device group and 312 to the control group. The annualized rate of all hospitalizations for heart failure within 24 months was 35.8% per patient-year in the device group as compared with 67.9% per patient-year in the control group (hazard ratio, 0.53; 95% confidence interval [CI], 0.40 to 0.70; P<0.001). The rate of freedom from device-related complications at 12 months was 96.6% (lower 95% confidence limit, 94.8%; P<0.001 for comparison with the performance goal). Death from any cause within 24 months occurred in 29.1% of the patients in the device group as compared with 46.1% in the control group (hazard ratio, 0.62; 95% CI, 0.46 to 0.82; P<0.001). CONCLUSIONS: Among patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite the use of maximal doses of guideline-directed medical therapy, transcatheter mitral-valve repair resulted in a lower rate of hospitalization for heart failure and lower all-cause mortality within 24 months of follow-up than medical therapy alone. The rate of freedom from device-related complications exceeded a prespecified safety threshold. (Funded by Abbott; COAPT ClinicalTrials.gov number, NCT01626079 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The magnitude of the tirzepatide-mediated improvement in the win ratio was large and similar to the effect of transcatheter mitral valve repair in patients with HF and secondary mitral regurgitation.32”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [32]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2017 ESC/EACTS Guidelines for the management of valvular heart disease
Baumgartner, H., Falk, V., Bax, J. J., De Bonis, M., Hamm, C., Holm, P. J., Iung, B., Lancellotti, P., Lansac, E., Rodriguez Muñoz, D., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx391 · Cited by 6,243
Zoghbi, W. A., Enriquez-Sarano, M., Foster, E., Grayburn, P. A., Kraft, C. D., Levine, R. A., Nihoyannopoulos, P., Otto, C. M., Quinones, M. A., Rakowski, H., et al. (2003) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(03)00335-3 · Cited by 4,044
Self-citation2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Self-citationNishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Fleisher, L. A., Jneid, H., Mack, M. J., McLeod, C. J., O’Gara, P. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.011 · Cited by 3,339
Self-citationPercutaneous Repair or Surgery for Mitral Regurgitation
Feldman, T., Foster, E., Glower, D. D., Kar, S., Rinaldi, M. J., Fail, P. S., Smalling, R. W., Siegel, R., Rose, G. A., Engeron, E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009355 · Cited by 2,183
Self-citationThe prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation
Goldstein, D., Moskowitz, A. J., Gelijns, A. C., Ailawadi, G., Parides, M. K., Perrault, L. P., Hung, J. W., Voisine, P., Dagenais, F., Gillinov, A. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512913 · Cited by 972
Self-citationPercutaneous Mitral Valve Interventions in the Real World
Maisano, F., Franzen, O., Baldus, S., Schäfer, U., Hausleiter, J., Butter, C., Ussia, G. P., Sievert, H., Richardt, G., Widder, J. D., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.094 · Cited by 839
Stone, G. W., Adams, D. H., Abraham, W. T., Kappetein, A. P., Généreux, P., Vranckx, P., Mehran, R., Kuck, K.-H., Leon, M. B., Piazza, N., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.049 · Cited by 594
Self-citationSecondary Mitral Regurgitation in Heart Failure
Asgar, A. W., Mack, M. J., & Stone, G. W. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.009 · Cited by 489
Self-citation
Research works printed but not linked: 1
- 16. cancer events. Biostatistics 2007; 8: 70821.
Cited by
Items 801–900 of 1,001
Paukovitsch, M., Schneider, L. M., Reichart, C., Nita, N., Rottbauer, W., Keßler, M., & Markovic, S. (2021) · Open Heart · doi:10.1136/openhrt-2021-001732 · Cited by 13
Medvedovsky, A. T., Haberman, D., Ibrahimli, M., Tonchev, I., Rashi, Y., Peretz, A., Shimoni, S., Tuvali, O., Danenberg, H. D., Beeri, R., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245849 · Cited by 13
Prevalence of left ventricular thrombus formation after mitral valve edge-to-edge repair
Tichelbäcker, T., Körber, M. I., Mauri, V., Iliadis, C., Metze, C., Adler, C., Baldus, S. E., Rudolph, V., Halbach, M., Pfister, R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12944-5 · Cited by 13
Grave, C., Tribouilloy, C. M., Tuppin, P., Weill, A., Gabet, A., Juillière, Y., Cinaud, A., & Olié, V. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123289 · Cited by 13
Transcatheter Interventions in Patients With Adult Congenital Heart Disease
Tan, W., Schmidt, A. C. S., Horlick, E. M., & Aboulhosn, J. (2022) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2022.100438 · Cited by 13
“…use of MitraClips (Abbott) has been established as an effective therapy in adult patients with primary and secondary mitral valve regurgitation 107,108 but has also been demonstrated to be effective in a select group of patients with CHD, mainly those with systemic atrioventricular valves…”
MethodOutcomes of Transcatheter Edge-to-Edge Repair in Degenerative vs. Functional Mitral Regurgitation
Kheifets, M., Angelini, F., D’Ascenzo, F., Pidello, S., Engelstein, H., Bocchino, P. P., Boretto, P., Frea, S., Levi, A., Assa, H. V., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206010 · Cited by 13
Role of the mitral valve in left ventricular assist device pathophysiology
Noly, P., Duggal, N., Jiang, M., Nordsletten, D., Bonini, M., Lei, I., Ela, A. S. A. A. A. E., Haft, J. W., Pagani, F. D., CASCINO, T. M., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1018295 · Cited by 13
Cammalleri, V., Antonelli, G., Luca, V. M. D., Carpenito, M., Nusca, A., Bono, M. C., Mega, S., Ussia, G. P., & Grigioni, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093316 · Cited by 13
“…Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) and Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation (MITRA-FR) trials compared the TEER with the MitraClip device vs. GDMT in patients with FMR [66,67].”
MethodHagendorff, A., Helfen, A., Brandt, R. R., Knebel, F., Altiok, E., Ewers, A., Haghi, D., Knierim, J., Merke, N., Romero-Dorta, E., et al. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02227-y · Cited by 13
Vincent, F., Redfors, B., Kotinkaduwa, L. N., Kar, S., Lim, D. S., Mishell, J. M., Whisenant, B. K., Lindenfeld, J. M., Abraham, W. T., Mack, M. J., et al. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2023.03.023 · Cited by 13
Self-citationAusbuettel, F., Barth, S., Chatzis, G., Fischer, D., Kerber, S., Mueller, J., List, S., Halbfaß, P., Deneke, T., NEF, H. M., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1229651 · Cited by 13
“Here, the multidisciplinary heart teams mainly oriented on the echocardiographic criteria defined in the Endovascular Valve Edge-to-Edge Repair Study (EVEREST) II for primary MR and on those defined in the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Function…”
BackgroundMethodRestoration of Life Expectancy After Transcatheter Edge-to-Edge Mitral Valve Repair
Biasco, L., Klersy, C., Benfari, G., Biaggi, P., Corti, R., Curti, M., Gaemperli, O., Jeger, R. V., Maisano, F., Mueller, O., et al. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2023.06.014 · Cited by 13
Heart Failure and Secondary Mitral Regurgitation: A Contemporary Review
Camaj, A., Thourani, V. H., Gillam, L. D., & Stone, G. W. (2023) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2023.101195 · Cited by 13
“11,15 The 2020 American Heart Association/American College of Cardiology guidelines provide a class IIa recommendation for MV surgery in patients undergoing coronary artery bypass grafting (CABG).”
BackgroundMethodInfluentialSelf-citationMitsis, A., Kyriakou, M., Christodoulou, E., Sakellaropoulos, S., & Avraamides, P. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2502060 · Cited by 13
“…COAPT trial enrolled patients with symptomatic heart failure and moderate-to-severe or severe secondary MR, showing that TEER with the MitraClip device, in addition to medical therapy, significantly reduced heart failure hospitalizations and overall mortality compared to medical therapy alone [27].”
BackgroundMethodPlayford, D. A., Stewart, S., Harris, S. A., Scalia, G. M., Celermajer, D. S., Thomas, L., Paratz, E. D., Chan, Y., & Strange, G. A. (2024) · Heart · doi:10.1136/heartjnl-2024-324790 · Cited by 13
“The growing armamentarium of mitral valve therapies including transcatheter techniques such as the TEER and MVR, 3 4 29 and mitral annular reduction 5 systems means that at-risk patients previously not considered suitable surgical candidates, may now be considered for catheter-based valve therapy.”
Echocardiographic assessment of mitral regurgitation
Kagiyama, N., & Shrestha, S. (2019) · Journal of Medical Ultrasonics · doi:10.1007/s10396-019-00971-1 · Cited by 13
Maggiore, P., Anastasius, M. O., Huang, A. L., Blanke, P., & Leipsic, J. A. (2020) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.2020190106 · Cited by 13
Quantitative aortography assessment of aortic regurgitation
Modolo, R., Chang, C. C., Onuma, Y., Schultz, C. J., Tateishi, H., Abdelghani, M., Miyazaki, Y., Aben, J., Rutten, M. C. M., Pighi, M., et al. (2020) · EuroIntervention · doi:10.4244/eij-d-19-00879 · Cited by 13
Advances in Clinical Cardiology 2019: A Summary of Key Clinical Trials
Linden, K., Mailey, J. A., Kearney, A., & Menown, I. B. A. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01355-5 · Cited by 13
“In contrast, the COAPT trial previously reported that MitraClip was associated with a reduction in death and in rehospitalisation for heart failure at 24 months [28].”
ResultPapolla, C., Adda, J., Rique, A., Habib, G., & Rieu, R. (2020) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2020.03.008 · Cited by 13
Płońska‐Gościniak, E., Suwalski, P., Bartuś, S., Kukulski, T., Komar, M., Wojakowski, W., Grygier, M., Pruszczyk, P., Gąsior, Z., Huczek, Z., et al. (2020) · Kardiologia Polska · doi:10.33963/kp.15358 · Cited by 13
Multiple MitraClips: The balancing act between pressure gradient and regurgitation
Gooden, S. C.-M., Hatoum, H., Zhang, W., Boudoulas, K. D., & Dasi, L. P. (2020) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2020.05.049 · Cited by 13
Lee, C., Huang, W.-M., Tsai, Y.-L., Lu, D., Sung, S., Yu, W., Guo, C., & Chen, C.-H. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.04.035 · Cited by 13
Sex-based differences in mitral valve Re-operation after mitral valve repair: Truth or myth?
Hirji, S. A., Guetter, C. R., Trager, L. E., Yazdchi, F., Landino, S. M., Lee, J., Anastasopulos, A. J., Percy, E., McGurk, S., Pelletier, M. P., et al. (2020) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2020.06.069 · Cited by 13
Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis
Volz, M. J., Pleger, S. T., Weber, A., Geis, N. A., Hamed, S., Mereles, D., Hegenbart, U., Katus, H. A., Frey, N., Raake, P. W. J., et al. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13473 · Cited by 13
Complications Following Percutaneous Mitral Valve Edge-to-Edge Repair Using MitraClip
Shah, M. A., Dalak, F., Al-Samadi, F., Shah, S. H., & Qattea, M. B. (2021) · JACC Case Reports · doi:10.1016/j.jaccas.2020.12.046 · Cited by 13
“Percutaneous mitral valve edge-toedge repair using MitraClip (Abbott, Abbott Park, Illinois) has proven to be an effective and safe option in patients with symptomatic MR, with a significant reduction rate of hospitalization and all-cause mortality as compared with medical therapy alone (3,4).”
BackgroundOtto, S., Velichkov, M., Hamadanchi, A., Schulze, P. C., & Möbius‐Winkler, S. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0046 · Cited by 13
Current Status of Catheter-based Mitral Valve Replacement
Rawish, E., Schmidt, T., Eitel, I., & Frerker, C. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01524-0 · Cited by 13
Transcatheter Repair and Replacement Technologies for Mitral Regurgitation: a European Perspective
Ooms, J. F., & Mieghem, N. M. V. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01556-6 · Cited by 13
Musuku, S. R., Mustafa, M., Pulavarthi, M., Doshi, I., Zhang, Y., Luu, S., Naqvi, A. R., Sunesara, I., Richvalsky, T., Yukhvid, D., et al. (2021) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2021.12.008 · Cited by 13
Estler, B., Rudolph, V., Seleznova, Y., Shukri, A., Stock, S., & Müller, D. (2022) · The European Journal of Health Economics · doi:10.1007/s10198-022-01476-4 · Cited by 13
Jung, R. G., Simard, T., Santo, P. D., & Hibbert, B. M. (2022) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000952 · Cited by 13
“Traditionally, surgical intervention for mitral regurgitation in cardiogenic shock is reserved for selected DMR patients with unknown benefits in FMR [22,23], whereas transcatheter interventions are being increasingly employed in both DMR and FMR. Transcatheter mitral valve edge-to-edge repair (TEER) was first approve…”
BackgroundInfluentialSimulation of Mitral Valve Plasticity in Response to Myocardial Infarction
Rego, B. V., Khalighi, A. H., Gorman, J. H., Gorman, R. C., & Sacks, M. S. (2022) · Annals of Biomedical Engineering · doi:10.1007/s10439-022-03043-7 · Cited by 13
First described mitral clip in an adult extracardiac Fontan patient: a case report
Haeffele, C. L., Lui, G. K., Peng, L. F., Chan, F. P., & Sharma, R. P. (2022) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytac479 · Cited by 13
Mitral valve repair using edge-to-edge technique in various situations: real-world experiences
Hirji, S. A., Val, F. R. D., Yazdchi, F., Lee, J., Ejiofor, J. I., Kolkailah, A. A., Chowdhury, R., McGurk, S., & Kaneko, T. (2019) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezz130 · Cited by 13
Transcatheter therapy for residual mitral regurgitation after MitraClip therapy
Niikura, H., Bae, R. Y., Gössl, M., Lin, D., Jay, D. B., & Sorajja, P. (2019) · EuroIntervention · doi:10.4244/eij-d-18-01148 · Cited by 13
Sawalha, K., Al‐Akchar, M., Ibrahim, A. M., Buhnerkempe, M., Koester, C., Salih, M., Bhattarai, M., Tandan, N., Bhatt, D. L., & Hafiz, A. M. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29188 · Cited by 13
Is There a Future for Minimal Access and Robots in Cardiac Surgery?
Faerber, G., Mukharyamov, M., & Doenst, T. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10090380 · Cited by 12
“Often times, new interventions are even being tested against medial therapy, although surgery is considered the current gold standard [38,39].”
BackgroundMustafa, A., Basman, C. L., Cinelli, M. P., Goldberg, Y. H., Wang, D., Patel, V. H., Kaur, A., Singh, P., Wei, C., Paliwoda, E. D., et al. (2024) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.30988 · Cited by 12
“14 However, the low rates of mortality and other complications might suggest this therapy is safer than other emerging TMVR devices.”
BackgroundLancellotti, P., Sugimoto, T., & Bäck, M. (2024) · European Heart Journal Open · doi:10.1093/ehjopen/oeae084 · Cited by 12
Valvular Heart Disease—A New Evolving Paradigm
Nishimura, R. A., Ommen, S. R., Dearani, J. A., & Schaff, H. V. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.11.001 · Cited by 12
Quality of Life After Transcatheter Tricuspid Valve Repair: Results from the Tri.FR Trial
Istrătoaie, S., de Groote, P., Karam, N., Trochu, J., Leurent, G., Coisne, A., Roux, P.-Y. L., Ganivet, A., Bernard, A. B., Neylon, A. M., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15327 · Cited by 12
Overtchouk, P., Ali, W. B., Prendergast, B., Conradi, L., Hahn, R. T., Granada, J. F., & Modine, T. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01333-x · Cited by 12
Osteresch, R., Diehl, K., Schmucker, J., Ammar, A. B., Solyom, O., Dierks, P., Fach, A., Wienbergen, H., & Hambrecht, R. (2020) · Cardiology · doi:10.1159/000510283 · Cited by 12
Safety, effectiveness and costs of percutaneous mitral valve repair: A real-world prospective study
Willits, I., Keltie, K., de Belder, M., Henderson, R. A., Linker, N. J., Patrick, H. E., Powell, H., Berry, L., Speller, J., Urwin, S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251463 · Cited by 12
“Comparison of demographics, inclusion and exclusion criteria with the intervention arm of the COAPT study [19].”
BackgroundMethodResultInfluentialRandomized Trials Are Needed for Transcatheter Mitral Valve Replacement
Rogers, J. H., Sorajja, P., Thourani, V. H., Sharma, R. P., Chehab, B., Cowger, J. A., Heimansohn, D. A., Badhwar, V., Guerrero, M. E., & Ailawadi, G. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.06.014 · Cited by 12
“On the basis of the results of COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation Trial), TEER was recently added as a Class 2A recommendation for patients who have chronic severe SMR related to LV dysfunction, persistent symp…”
MethodHadaya, J. E., Tran, Z. K., Sanaiha, Y., Aguayo, E., Dobaria, V., Press, M. C., & Benharash, P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259863 · Cited by 12
“Transcatheter mitral valve repair (TMVR) has recently emerged as an alternative to surgery for the treatment of severe symptomatic MR, using catheter-based methods to appose the two leaflets in regions of malcoaptation [4, 5].”
MethodGalusko, V., Sekar, B., Ricci, F., Wong, K., Bhattacharyya, S., Mullen, M., Gallina, S., Ionescu, A., & Khanji, M. Y. (2021) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcab082 · Cited by 12
Pascual-Figal, D. A., González‐Juanatey, J. R., Bayés‐Genís, A., Cobo, M., Delgado, J. F., Molina, B. D., González‐Costello, J., López‐Fernández, S., Mesa-Rico, R., Villota, J. N., et al. (2022) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2021.11.023 · Cited by 12
“…in those who meet success criteria and IIb in those who do not; notably, the criteria of the COAPT study are included for candidate selection 11 but, strikingly, the surgical option continues to be favored, despite the lack of data supporting mitral valve surgery alone in these patients; b)…”
BackgroundNita, N., Schneider, L. M., Dahme, T., Markovic, S., Keßler, M., Rottbauer, W., & Tadić, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.850356 · Cited by 12
“532 30-day mortality (%) 12 (6) 10 (5) 10 (5) 7 (4) 6 (3) 0.”
BackgroundResultInfluentialImpact of Persistent Iatrogenic Atrial Septal Defect following MitraClip
Chao, C., Seri, A. R., Abraham, B., Farina, J., Fennelly, E., Campany, M. E., Pereyra, M., Said, E. F., Kenyon, C. R., Fath, A. R., et al. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10010001 · Cited by 12
“Introduction Transcatheter edge-to-edge mitral valve repair (TEER) has emerged as a treatment option for severe mitral regurgitation (MR) in patients with high surgical risk [1].”
BackgroundKang, Y., Gao, J., Wang, W.-X., Yu-hu, M., Wang, W., He, S. E., Xu, X., Li, P., & You, T. (2023) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-023-02123-6 · Cited by 12
The Emerging Role of Artificial Intelligence in Valvular Heart Disease
Canning, C., Guo, J., Narang, A., Thomas, J. D., & Ahmad, F. S. (2023) · Heart Failure Clinics · doi:10.1016/j.hfc.2023.03.001 · Cited by 12
Miura, M., Okuda, S., Murata, K., Ohno, Y., Katou, S., Nakao, F., Ueyama, T., Yamamoto, T., & Ikeda, Y. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1190548 · Cited by 13
“Although new pharmacological (5, 6) and non-pharmacological therapies (7, 8) have been developed in the past decade, prognostic improvement in HF patients remains inadequate (9).”
BackgroundContemporary Review of Transcatheter Mitral Valve Interventions for Mitral Regurgitation
Chan, N., Dong, T. A., Sabbak, N., Xu, B., & Wang, T. K. M. (2023) · Life · doi:10.3390/life13071511 · Cited by 12
“with the rate of freedom from clip-related complications exceeding the prespecified safety threshold [18].”
BackgroundPark, S. M., Lee, S. Y., Jung, M., Youn, J., Kim, D., Cho, J. Y., Cho, D., Hyun, J., Cho, H., Park, S., et al. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0114 · Cited by 12
Ktenopoulos, N., Katsaros, O., Apostolos, A., Drakopoulou, M., Tsigkas, G., Tsioufis, C., Davlouros, P. A., Toutouzas, K. P., & Καρανάσος, Α. (2024) · Life · doi:10.3390/life14070842 · Cited by 12
Öztürk, C., Fasell, T., Sinning, J., Werner, N., Nickenig, G., Hammerstingl, C., & Schueler, R. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.28775 · Cited by 12
Transcatheter mitral valve repair for functional mitral regurgitation: Evaluating the evidence
Gelijns, A. C., Moskowitz, A. J., O’Gara, P. T., Giustino, G., Mack, M. J., MANCINI, D. M., Bagiella, E., Hung, J., Ailawadi, G., Leon, M. B., et al. (2020) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2020.02.132 · Cited by 12
“Gelijns, PhD, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1077, New York, NY 10029, Phone: (1) 212 659 9567, Fax: (1) 212-423-2998, Annetine.”
InfluentialSelf-citationMethodologic Considerations on Four Cardiovascular Interventions Trials With Contradictory Results
Gaudino, M. F. L., Ruel, M., Obadia, J., Bonis, M. D., Puskas, J. D., Biondi‐Zoccai, G., Angiolillo, D. J., Charlson, M. E., Crea, F., & Taggart, D. P. (2020) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.04.107 · Cited by 12
Rezapour, A., Azari, S., Arabloo, J., Pourasghari, H., Behzadifar, M., Alipour, V., Omidi, N., Sadeghian, S., Aghajani, H., & Bragazzi, N. L. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10055-9 · Cited by 12
“1% in the medical therapy alone (control group) [22].”
BackgroundKhan, M. S., Friede, T., Anker, S. D., & Butler, J. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13301 · Cited by 12
Mitral and Tricuspid Valves Percutaneous Repair in Patients with Advanced Heart Failure
Cammalleri, V., Mega, S., Ussia, G. P., & Grigioni, F. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.05.006 · Cited by 12
Wojakowski, W., Chmielak, Z., Widenka, K., Pręgowski, J., Perek, B., Gackowski, A., Bartuś, K., Szymański, P., Deja, M. A., Kalarus, Z. F., et al. (2021) · Kardiologia Polska · doi:10.33963/kp.a2021.0116 · Cited by 12
Siddiqi, T. J., Usman, M., Ahmed, J., Shahid, I., Ahmed, W., & Alkhouli, M. (2022) · Future Cardiology · doi:10.2217/fca-2021-0061 · Cited by 12
Simard, T., Reddy, Y. N. V., Thaden, J. J., Padang, R., Michelena, H. I., Nkomo, V. T., Lloyd, J. W., Sabbagh, A. E., Nishimura, R. A., Reeder, G. S., et al. (2022) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.30224 · Cited by 12
Chiarito, M., Sanz‐Sánchez, J., Pighi, M., Cannata, F., Rubbio, A. P., Munafò, A. R., Cao, D., Roccasalva, F., Pini, D., Pagnotta, P. A., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13772 · Cited by 12
Menezes, M. N., da Silva, M. T., Magalhães, A., Melica, B., Toste, J., Calé, R., Almeida, M., Fiúza, M., & de Oliveira, E. I. (2023) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2023.04.013 · Cited by 12
MitraClip: How Do We Reconcile the Inconsistent Findings of MITRA-FR and COAPT?
Mauricio, R., & Kumbhani, D. J. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1239-0 · Cited by 12
Tan, W., Press, M. C., Lluri, G., & Aboulhosn, J. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.28782 · Cited by 12
Keller, K., Hobohm, L., Geyer, M., Kreidel, F., Ostad, M. A., Lavie, C. J., Lankeit, M., Konstantinides, S., Münzel, T. F., & von Bardeleben, R. S. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.04.009 · Cited by 12
Proportionate or disproportionate secondary mitral regurgitation: how to untangle the Gordian knot?
Kamoen, V., Calle, S., Buyzere, M. D., & Timmermans, F. (2020) · Heart · doi:10.1136/heartjnl-2020-317040 · Cited by 12
“11 However, because of the limitations on the assumptions made from the echocardiographic COAPT and MITRA-FR data, 9 12 and because RV values are not reported in COAPT, 8 40 the use or comparisons between EROA/LVEDV and RV/LVEDV may not be valid at this time, but this issue should be further investigated along with gr…”
InfluentialComparison of transcatheter tricuspid valve repair using the MitraClip NTR and XTR systems
Ali, F. M., Ong, G., Edwards, J. M., Connelly, K. A., & Fam, N. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.11.073 · Cited by 12
Bernard, J., Kalavrouziotis, D., Marzouk, M., Nader, J., Bernier, M., Pîbarot, P., & Mohammadi, S. (2021) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.01.094 · Cited by 12
Praz, F., Windecker, S., & Kapadia, S. R. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.05.006 · Cited by 12
Self-citationGeschlechterspezifische Aspekte kardiovaskulärer Erkrankungen
Baessler, A., Bauer, P., Becker, M., Berrisch-Rahmel, S., Goldmann, B. U., Grünig, E., Hamm, C., Meder, B., Kindermann, I., Ong, P., et al. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00694-9 · Cited by 11
Iatrogenic atrial septal defects in structural heart interventions: Opening the Pandora's box
Dimitriadis, K. S., Pyrpyris, N., Karampinos, K. I., Malainou, C. P., Beneki, E., KOULOURIOTIS, A., Pitsiori, D., Aznaouridis, K. A., Aggeli, C., & Tsioufis, K. P. (2024) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.31237 · Cited by 11
“26 This procedure requires the introduction of a large bore delivery guide (usually 22 F) through the interatrial septum to facilitate the placement of the device.”
Sugiura, A., Tanaka, T., Kavsur, R., Öztürk, C., Vogelhuber, J., Silaschi, M., Weber, M., Zimmer, S., & Nickenig, G. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.03.009 · Cited by 11
Antiplatelet Therapy in Heart Disease
Özyüncü, N. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm36522 · Cited by 11
“In the absence of specific guidelines, antithrombotic therapy after TEER is guided by protocols from clinical trials and tailored to patient characteristics [134–137].”
Adamo, M., Pagnesi, M., Marsan, N. A., Bauersachs, J. K., Hausleiter, J., Zieroth, S. R., & Metra, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf480 · Cited by 11
Initial clinical experience with VersaCross transseptal system for transcatheter mitral valve repair
Sayah, N., Simon, F., Garceau, P., Ducharme, A., Basmadjian, A., Bouchard, D., Pellerin, M., Bonan, R., & Asgar, A. (2020) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.29365 · Cited by 11
“Transcatheter mitral valve repair is becoming ever more prevalent for the treatment of high risk primary mitral regurgitation and secondary mitral regurgitation since the publication of the COAPT trial.(5) The procedure requires a precise transseptal puncture between 3.”
BackgroundAgarwal, V., Kaple, R., Mehta, H. H., Singh, P., & Bapat, V. (2021) · Annals of Cardiothoracic Surgery · doi:10.21037/acs-2021-tviv-80 · Cited by 11
Meijerink, F., de Witte, S. M., Limpens, J., de Winter, R. J., Bouma, B. J., & Baan, J. (2022) · Heart Lung and Circulation · doi:10.1016/j.hlc.2021.11.017 · Cited by 11
Bell, S. P., & Rich, M. W. (2021) · Springer eBooks · doi:10.1007/978-3-030-76271-1_19 · Cited by 11
Guideline-directed medical therapy after transcatheter edge-to-edge mitral valve repair
Tanaka, T., Kavsur, R., Spieker, M., Iliadis, C., Metze, C., Brachtendorf, B. M., Horn, P., Zachoval, C., Sugiura, A., Kelm, M., et al. (2022) · Heart · doi:10.1136/heartjnl-2022-320826 · Cited by 11
Glikson, M., Nielsen, J. C., Kronborg, M. B., Michowitz, Y., Auricchio, A., Barbash, I. M., Barrabés, J. A., Boriani, G., Braunschweig, F., Brignole, M., et al. (2022) · Giornale Ialiano di Cardiologia · doi:10.1714/3824.38087 · Cited by 11
Baldus, S. E., Bauersachs, J., Beckmann, A., Bleiziffer, S., Böning, A., Conradi, L., Ensminger, S. M., Falk, V., Frerker, C., Liebetrau, C., et al. (2022) · Die Kardiologie · doi:10.1007/s12181-022-00555-3 · Cited by 11
Freixa, X., Tolosana, J. M., Guillén, P. L. C., Hernández‐Enríquez, M., Sanchís, L., Flores‐Umanzor, E., Farrero, M., Andrea, R., Roqué, M., Carretero, M. J., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009501 · Cited by 11
Impact of secondary mitral regurgitation on survival in atrial and ventricular dysfunction
Mori, M., Zogg, C. K., Amabile, A., Fereydooni, S., Agarwal, R., Weininger, G., Krane, M., Sugeng, L., & Geirsson, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277385 · Cited by 11
“Therefore, understanding the optimal treatment threshold and approach further requires mechanistic insights into the etiology of the AFMR.”
BackgroundMethodInfluentialMcKellar, S. H., Harkness, J., Reid, B. B., Sekaran, N. K., May, H. T., & Whisenant, B. K. (2023) · JTCVS Open · doi:10.1016/j.xjon.2023.10.019 · Cited by 11
Self-citationNatriuretic peptide testing strategies in heart failure: A 2023 update
Chaikijurajai, T., Rincon-Choles, H., & Tang, W. H. W. (2023) · Advances in clinical chemistry · doi:10.1016/bs.acc.2023.11.005 · Cited by 11
von Stein, P., Besler, C., Riebisch, M., Al‐Hammadi, O., Ruf, T. F., Gerçek, M., Grothusen, C., Mehr, M., Becher, M. U., Friedrichs, K. P., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031881 · Cited by 11
Saito, T., Kuno, T., Ueyama, H. A., Kampaktsis, P. Ν., Kolte, D. S., Misumida, N., Takagi, H., Aikawa, T., & Latib, A. (2023) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.30944 · Cited by 11
Lucà, F., Pavan, D., Gulizia, M. M., Manes, M. T., Abrignani, M. G., Benedetto, F. A., Bisceglia, I., Brigido, S., Caldarola, P., Calvanese, R., et al. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae034 · Cited by 11
Biasco, L., Tersalvi, G., Klersy, C., Benfari, G., Biaggi, P., Corti, R., Curti, M., Gaemperli, O., Jeger, R. V., Maisano, F., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032706 · Cited by 11
“16,20,21 The clinical profile of our population replicates data derived from surgical series and registries on TEER, indicating that women are referred for intervention at an older age and with a worse functional capacity as compared with men.”
Morikawa, T., Enta, Y., Sakamoto, T., Yamamoto, M., Ueno, H., Yagasaki, H., Asch, F. M., Dong, M. L., Peterman, K., Rodríguez, E., et al. (2024) · JACC Asia · doi:10.1016/j.jacasi.2024.08.003 · Cited by 11
Device therapies for heart failure with reduced ejection fraction: a new era
Mody, R., Sheth, A. B. N., Dash, D., Mody, B., Agrawal, A., Monga, I. S., Rastogi, L., & Munjal, A. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1388232 · Cited by 11
Saxon, J. T., Généreux, P., Ninios, V. N., Waggoner, T. E., Tahirkheli, N. K., Grygier, M., Wróbel, K., Adam, M., Nickenig, G., Kaneko, T., et al. (2025) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.124.014985 · Cited by 11
“11 In a subgroup analysis of the EXPAND registry (A Contemporary, Prospective Study Evaluating Real-World Experience of Performance and Safety for the Next Generation of MitraClip Devices), Sodhi et al 4 reported a 94% procedural success of MTEER, with substantial health status benefits comparable…”
Hussey, P. T., Wu, I., & Johnston, T. A. (2019) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.01.006 · Cited by 11
Kheiri, B., Zayed, Y., Barbarawi, M., Osman, M., Chahine, A., Ahmed, S. A., Bachuwa, G. I., Hassan, M., Alkhouli, M. A., Feldman, T. E., et al. (2019) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2019.04.008 · Cited by 11
Metadata
- Authors
- Stone, G. W., Lindenfeld, J., Abraham, W. T., Kar, S., Lim, D. S., Mishell, J. M., Whisenant, B., Grayburn, P. A., Rinaldi, M., Kapadia, S. R., Rajagopal, V., Sarembock, I. J., Brieke, A., Marx, S. O., Cohen, D. J., Weissman, N. J., & Mack, M. J.
- Affiliations
- NewYork–Presbyterian Hospital (US)
- Cedars-Sinai Medical Center (US)
- Cleveland Clinic (US)
- University of Colorado Hospital (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-12-13
- Volume
- 379
- Issue
- 24
- Pages
- 2307-2318
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2889688444
- Cited by
- 3,017
- References
- 23
- Citations by year
- 2026: 253 · 2025: 330 · 2024: 308 · 2023: 372 · 2022: 385 · 2021: 486 · 2020: 453 · 2019: 376 · 2018: 42
- FWCI
- 256.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Surgery › Cardiac Structural Anomalies and Repair
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Keywords
- transcatheter mitral valve repair, heart failure, functional mitral regurgitation, left ventricular dysfunction, heart failure hospitalization, all-cause mortality, device complications, guideline-directed medical therapy, COAPT trial, transcatheter edge-to-edge repair, mitral valve repair, transcatheter closure devices, transcatheter aortic valve implantation, transcatheter mitral valve replacement
- MeSH terms
- Aged, Aged, 80 and over, Combined Modality Therapy, Female, Heart Failure, Heart Valve Prosthesis, Hospitalization, Humans, Male, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Prosthesis Failure, Stroke Volume, Treatment Outcome, Ventricular Dysfunction, Left, Heart Valve Prosthesis Implantation, Kaplan-Meier Estimate, Intention to Treat Analysis, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.